Illumina outlines 2026 revenue guidance of $4.5B-$4.6B while advancing clinical growth and multiomics strategy
Source: SeekingAlpha
2026-02-05 20:15:05 ET
More on Illumina
- Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
- Illumina, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Illumina: What Is Next In This Sequence?
- Illumina Non-GAAP EPS of $1.35 beats by $0.12, revenue of $1.16B beats by $50M
- Illumina Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Illumina outlines 2026 revenue guidance of $4.5B–$4.6B while advancing clinical growth and multiomics strategy
Illumina Inc.
NASDAQ: ILMN
ILMN Trading
-1.2% G/L:
$122.73 Last:
452,105 Volume:
$124.32 Open:
ILMN Latest News
March 05, 2026 09:15:00 am
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
February 27, 2026 09:15:00 am
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
February 25, 2026 09:15:00 am
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
February 24, 2026 12:15:00 pm
Illumina launches TruPath Genome, setting a new standard in genomic insight
ILMN Stock Data
$18,085,408,000
148,827,200
0.13%
404
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
